Neurocrine Biosciences missed earnings estimates but saw revenue growth, while insiders sold shares.

Neurocrine Biosciences reported second-quarter earnings of $1.88 EPS, slightly below estimates, with $805.5 million in revenue, up 28.3% year-over-year. The stock closed at $129.78, with a market cap of $13.02 billion and a consensus "Moderate Buy" rating. Boone Capital Management reduced its stake by 13,924 shares, and insiders sold 42,590 shares valued at $5.78 million in three months. Analysts forecast $4.28 EPS for the year, and the company’s lead drug, Ingrezza, treats tardive dyskinesia.